Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide
and lead to more than 50,000 deaths annually. The diseases are caused by infection with …

Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …

Combination therapy for the treatment of visceral leishmaniasis has increasingly been
advocated as a way to increase treatment efficacy and tolerance, reduce treatment duration …

Miltefosine, the only oral drug approved for the treatment of leishmaniasis—a parasitic
disease transmitted by sandflies—is considered as a success story of research and …

Quantifying the uncertainty around endpoints used for decision-making in drug development
is essential. In nonlinear mixed-effects models (NLMEM) analysis, this uncertainty is derived …

Background. Recent reports indicated high miltefosine treatment failure rates for visceral
leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological …

Background Treatment for post-kala-azar dermal leishmaniasis (PKDL) in Sudan is currently
recommended only for patients with persistent or severe disease, mainly because of the …